There are currently 1471 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514
Recruiting
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Clinical Study Site, Dallas, Texas
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Prediction of Neoadjuvant Chemotherapy Response Using Contrast-Enhanced Ultrasound in Patients With Locally Advanced Breast Cancer
NCT04715958
Recruiting
This phase II/III trial studies if contrast-enhanced ultrasounds using a contrast dye, perflutren lipid microspheres (Definity), can predict the response to chemotherapy by estimating the pressure in the cancer in patients with breast cancer that has spread to nearby tissues and lymph nodes (locally advanced). The efficacy of cancer therapy is affected by the pressure in the cancer. Definity is a contrast dye used to create better images during ultrasounds. The purpose of this trial is to determ... Read More
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
04/24/2025
Locations: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Conditions: Anatomic Stage III Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma
Register for Updates
Evaluate REC-4881 in Patients With FAP
NCT05552755
Recruiting
This is a multicenter, two-part trial in participants with Familial Adenomatous Polyposis (FAP).
Gender:
ALL
Ages:
55 years and above
Trial Updated:
04/24/2025
Locations: Genetic Cancer Prevention Clinic - UT Southwestern, Dallas, Texas
Conditions: Familial Adenomatous Polyposis
Register for Updates
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
NCT06435000
Recruiting
This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
04/24/2025
Locations: Retina Foundation of the Southwest, Dallas, Texas
Conditions: Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
Register for Updates
Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT
NCT05399537
Recruiting
Prismocitrate 18 is a continuous renal replacement therapy (CRRT) solution to be used as a renal replacement solution and as an anticoagulant to prevent blood clotting in the extracorporeal circuit. The delivery of CRRT therapy is provided by the PrisMax System which includes regional citrate anticoagulation (RCA) software to facilitate citrate and calcium compensation prescription. The objectives of this study are: 1) to confirm the safety of Prismocitrate 18 in patients receiving CRRT using c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury (AKI)
Register for Updates
Targeting Breathing Limitations to Improve Functional Outcomes in HFpEF
NCT05723679
Recruiting
The overall purpose of this study is to investigate whether pulmonary limitations that increase the oxygen (O2) cost of breathing impact dyspnea on exertion (DOE) and peak exercise capacity in patients with HFpEF and obesity. As per investigator's hypothesis, obesity is likely a significant contributor to DOE and exercise intolerance in patients with HFpEF.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
04/23/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Heart Failure With Preserved Ejection Fraction, Obesity
Register for Updates
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
NCT05900986
Recruiting
The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) injection in female patients undergoing partial mastectomy for DCIS (whether or not undergoing planned SLNB) or Stage I-II primary invasive breast cancer undergoing SLNB. Safety is the primary objective of this study, followed by efficacy that will be assessed fr... Read More
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
04/23/2025
Locations: Integro Theranostics Research Site #3, Dallas, Texas
Conditions: Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
Register for Updates
Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation
NCT06130059
Recruiting
The purpose of this research study is to determine the effectiveness of low dose colchicine (LoDoCo) on measures of exercise capacity, physical function, frailty, and quality of life, among patients with heart failure with chronic stable preserved ejection fraction (HFpEF) and systemic inflammation. The use of LoDoCo in this study is considered investigational as it has not been approved by the Food and Drug Administration (FDA) for the treatment of exercise capacity in patients with HFpEF. Par... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/23/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Heart Failure, Inflammation
Register for Updates
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Baylor Scott & White Research Institute, Baylor University Medical Center, Dallas, Texas
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Conditioning SCID Infants Diagnosed Early
NCT03619551
Recruiting
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related dono... Read More
Gender:
ALL
Ages:
Between 0 years and 2 years
Trial Updated:
04/22/2025
Locations: Children's Medical Center Dallas, Dallas, Texas
Conditions: SCID
Register for Updates
Deliver-EE: Evaluating Effects of Meal Delivery
NCT05357261
Recruiting
This study will randomly assign 2,300 older adults on waiting lists at fourteen Meals on Wheels programs in Florida, Illinois, Maryland, Tennessee, Texas, North Carolina, South Carolina, and California into two groups who will receive: (a) daily delivery of meals, five days a week or (b) a shipment of 10 frozen meals, every two weeks. Researchers will examine participants' Medicare claims to understand if differences in healthcare utilization occur between the two groups within six months after... Read More
Gender:
ALL
Ages:
66 years and above
Trial Updated:
04/21/2025
Locations: Visiting Nurse Association of Texas, Dallas, Texas
Conditions: Healthy
Register for Updates
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941
Recruiting
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis... Read More
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
04/21/2025
Locations: Univ of Texas Southwest Med Center, Dallas, Texas
Conditions: Prostate Cancer
Register for Updates